208 related articles for article (PubMed ID: 26494859)
21. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
23. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
24. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
25. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
26. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
27. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
29. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.
Mouraret N; Marcos E; Abid S; Gary-Bobo G; Saker M; Houssaini A; Dubois-Rande JL; Boyer L; Boczkowski J; Derumeaux G; Amsellem V; Adnot S
Circulation; 2013 Apr; 127(16):1664-76. PubMed ID: 23513067
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
Cipriano R; Patton JT; Mayo LD; Jackson MW
Cell Cycle; 2010 Apr; 9(7):1373-9. PubMed ID: 20305378
[TBL] [Abstract][Full Text] [Related]
31. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
32. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
[TBL] [Abstract][Full Text] [Related]
33. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
[TBL] [Abstract][Full Text] [Related]
34. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
35. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.
Mulay SR; Thomasova D; Ryu M; Anders HJ
Kidney Int; 2012 Jun; 81(12):1199-211. PubMed ID: 22297670
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
37. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
[TBL] [Abstract][Full Text] [Related]
38. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.
Anil B; Riedinger C; Endicott JA; Noble ME
Acta Crystallogr D Biol Crystallogr; 2013 Aug; 69(Pt 8):1358-66. PubMed ID: 23897459
[TBL] [Abstract][Full Text] [Related]
39. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
40. On p53 revival using system oriented drug dosage design.
Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S
J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]